Neumora Therapeutics, Inc.

By person

16 insiders · 76 transactions

16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ARCH Venture Partners X, LLC entity

10% owner

$56.00M (3)

—

+$56.00M

6,046,907

3.22%

$9.65M

—

Burow Kristina

Director

$36.43M (20)

—

+$36.43M

6,094,624

3.24%

$9.73M

—

AMGEN INC entity

10% owner

$30.00M (1)

—

+$30.00M

35,368,653

18.82%

$56.44M

—

ARCH Venture Partners XII, LLC entity

10% owner

$10.93M (19)

—

+$10.93M

6,046,907

3.22%

$9.65M

+246.6%

Pinto Joshua

President & CEO

—

$1.20M (6) scheduled

−$1.20M

209,950

0.1117%

$335.04K

−56.1%

Lenz Robert A.

Head of R&D

—

$1.09M (6) scheduled

−$1.09M

309,092

0.1645%

$493.25K

—

Aurora Daljit Singh

See Remarks

—

$1.04M (14) scheduled

−$1.04M

48,750

0.0259%

$77.80K

−78.7%

Fust Matthew K

Director

—

$370.96K (2) scheduled

−$370.96K

20,100

0.0107%

$32.08K

—

Gosebruch Henry O

President & CEO

$189.37K (1)

—

+$189.37K

477,345

0.2540%

$761.75K

+24.8%

BERNS PAUL L

See Remarks

—

$57.93K (2)

−$57.93K

7,395,185

3.94%

$11.80M

−3.3%

Milligan Michael Lee

See Remarks

—

$8.47K (2) scheduled

−$8.47K

21,034

0.0112%

$33.57K

+450.2%

Suh Carol Y.

Chief Operating Officer

—

374,674

0.1994%

$597.90K

+29.3%

FMR LLC entity

See Remark 1

—

88,289

0.0470%

$140.89K

—

Ho Maykin

Director

—

20,100

0.0107%

$32.08K

—

Piacquad David

Director

—

20,100

0.0107%

$32.08K

—

Halawa Alaa

Director

—

20,100

0.0107%

$32.08K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Milligan Michael Lee

17 Feb 2026

See Remarks

Sold on a plan

1,436

$3.57

$5.12K

Aurora Daljit Singh

11 Nov 2025

See Remarks

Sold on a plan indirect

114,703

$2.68

$307.03K

Pinto Joshua

18 Feb 2025

President

Sold on a plan

8,048

$1.67

$13.48K

Lenz Robert A.

18 Feb 2025

Head of R&D

Sold on a plan

5,614

$1.67

$9.38K

Aurora Daljit Singh

18 Feb 2025

Chief Strategy Officer

Sold on a plan

8,565

$1.68

$14.35K

Milligan Michael Lee

18 Feb 2025

See Remarks

Sold on a plan

1,978

$1.69

$3.35K

BERNS PAUL L

18 Feb 2025

See Remarks

Sold on a plan

13,871

$1.69

$23.47K

Lenz Robert A.

10 Oct 2024

Head of R&D

Sold on a plan

8,260

$15.09

$124.60K

Lenz Robert A.

9 Oct 2024

Head of R&D

Sold on a plan

5,563

$15.01

$83.51K

Lenz Robert A.

18 Sep 2024

Head of R&D

Sold on a plan

10,676

$12.09

$129.09K

Lenz Robert A.

17 Sep 2024

Head of R&D

Sold on a plan

30,788

$11.81

$363.74K

Lenz Robert A.

12 Sep 2024

Head of R&D

Sold on a plan

32,948

$11.43

$376.66K

Pinto Joshua

27 Aug 2024

Chief Financial Officer

Sold on a plan indirect

15,693

$11.39

$178.81K

Pinto Joshua

26 Aug 2024

Chief Financial Officer

Sold on a plan indirect

31,642

$11.78

$372.59K

Pinto Joshua

23 Aug 2024

Chief Financial Officer

Sold on a plan indirect

24,169

$11.59

$280.01K

Pinto Joshua

22 Aug 2024

Chief Financial Officer

Sold on a plan indirect

28,496

$11.63

$331.47K

Show all 76 transactions →

Neumora Therapeutics, Inc.

By person

Individual transactions

What was left out